Systemic glucocorticoid treatment is an important therapy for AECOPD that can reduce the rates of treatment failure and rehospitalization in patients with non-respiratory failure.[20] Although the recommended dose of systemic glucocorticoid have been proposed in the GOLD guidelines, differences in the dose and course of treatment remain in the clinic.[4,21] In our present study, we did not find a significant correlation between T-IgE and dose of systemic glucocorticoid in AECOPD, while it was still an important aspect in our further work, considering the vital role of the treatment. The gene discussed is IGHE; the disease is respiratory failure.